West Pharmaceutical Services (WST) reported Q1 adjusted earnings Thursday of $1.45 per diluted share, down from $1.56 a year earlier.

Analysts polled by FactSet expected $1.23.

Net sales for the quarter ended March 31 were $698 million, up from $695.4 million a year earlier. Analysts surveyed by FactSet expected $685.7 million.

For 2025, the company increased its adjusted EPS guidance range to now be between $6.15 and $6.35 from the prior outlook range of between $6 and $6.20. Analysts surveyed by FactSet expect $6.11.

The company also increased its full-year 2025 net sales guidance range to now be between $2.95 billion and $2.98 billion from the prior outlook range of between $2.88 billion and $2.91 billion. Analysts polled by FactSet expect $2.90 billion.

The company's board maintained its quarterly dividend at $0.21 per share, payable Aug. 6 to shareholders of record on July 30.

West Pharmaceutical Services shares were up over 3% in recent premarket activity.

Price: 224.17, Change: +5.99, Percent Change: +2.75